DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

and pravastatin across doses (STELLAR trial). Am J Cardiol,
2003, 92:152–160.
Kastelein JJ, et al. Simvarstatin with or without ezetimibe in familial
hypercholesterolemia. N Eng Jimed, 2008, 358:1431–1443.
Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and
disease. Nature, 2000, 405:421–424.
Knopp RH, Dujovne CA, Le Beaut A, et al. Evaluation of the
efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia:
A pooled analysis from two controlled phase
III clinical studies. Int J Clin Pract, 2003, 57:363–368.
Knopp RH, Retzlaff BM, Fish B, et al. The SLIM Study: Slo-
Niacin(r) and Atorvastatin Treatment of Lipoproteins and
Inflammatory Markers in combined hyperlipidemia. J Clin
Lipidol, 2009, 3:167–178.
Kuklina EV, Yoon PW, Keenan NL. Trends in high levels of lowdensity
lipoprotein cholesterol in the United States, 1999-
2006. JAMA, 2009, 302:2104–2110.
Law M, Rudnicka AR. Statin safety: A systematic review. Am J
Cardiol, 2006, 97(suppl):52C–60C.
Lee JH, O’Keefe JH, Bell D, et al. Vitamin D deficiency: An
important, common, and easily treatable cardiovascular risk
factor? J Am Coll Cardiol, 2008, 52:1949–1956.
Lewis JH, Mortensen ME, Zweig S, et al. Efficacy and safety of
high-dose pravastatin in hypercholesterolemic patients with
well-compensated chronic liver disease: Results of a prospective,
randomized, double-blind, placebo-controlled, multicenter
trial. Hepatology, 2007, 46:1453–1463.
Li HY, Appelbaum FR, Willman CL, et al. Cholesterol-modulating
agents kill acute myeloid leukemia cells and sensitize
them to therapeutics by blocking adaptive cholesterol
responses. Blood, 2003, 101:3628–3634.
Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryI coenzyme
A reductase inhibition beyond low-density lipoprotein
cholesterol. Am J Cardiol, 2005, 96(suppl):24F–33F.
Libby P, Aikawa M. Mechanisms of plaque stabilization with
statins. Am J Cardiol, 2003, 91(suppl):4B–8B.
Libby P, Ridker PM. Inflammation and atherosclerosis: Role of C-
reactive protein in risk assessment. Am J Med, 2004, 116:9S–16S.
Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK.
LDL receptor-related protein 1: Unique tissue-specific functions
revealed by selective gene knockout studies. Physiol Rev,
2008, 88:887–918.
Lipid Research Clinics Program. The Lipid Research Clinics
Coronary Primary Prevention Trial results. II. The relationship
of reduction in incidence of coronary heart disease to cholesterol
lowering. JAMA, 1984, 251:365–374.
Liu J, Hong Y, D’Agostino RB Sr, et al. Predictive value for the
Chinese population of the Framingham CHD risk assessment
tool compared with the Chinese Multi-provincial Cohort
Study. JAMA, 2004, 291:2591–2599.
Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and
stroke statistics 2009 update: A report from the American
Heart Association Statistics Committee and Stroke Statistics
Subcommittee. Circulation, 2009, 119:e21–e181.
Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and setting
national goals for cardiovascular health promotion and disease
reduction. The American Heart Association’s strategic impact
goal through 2020 and beyond. Circulation, 2010, 121:586–613.
Lloyd-Jones DM, Nam B-H, D’Agostino RB Sr, et al. Parental
cardiovascular disease as a risk factor for cardiovascular disease
in middle-aged adults. A prospective study of parents and
offspring. JAMA, 2004, 291:2204–2211.
Lloyd-Jones DM, Tian L. Predicting cardiovascular risk: So what
do we do now? Ann Intern Med, 2006, 166:1342–1344.
Lorenzen A, Stannek C, Lang H, et al. Characterization of a G
protein-coupled receptor for nicotinic acid. Mol Pharmacol,
2001, 59:349–357.
Mahley RW, Weisgraber KH, Bersot TP. Disorders of lipid
metabolism. In: Kronenberg HM, Melmed S, Polonsky KS,
Larsen PR, eds. Williams Textbook of Endocrinology, 11th ed.,
Philadelphia, Saunders, 2008, pp. 1589–1653.
McLaughlin T, Reaven G, Abbasi F, et al. Is there a simple way
to identify insulin-resistant individuals at increased risk of cardiovascular
disease? Am J Cardiol, 2005, 96:399–404.
Melani L, Mills R, Hassman D, et al. Efficacy and safety of ezetimibe
coadministered with pravastatin in patients with primary
hypercholesterolemia: A prospective, randomized,
double-blind trial. Eur Heart J, 2003, 24:717–728.
Miettinen TA, Gylling H. Synthesis and absorption markers of
cholesterol in serum and lipoproteins during a large dose of
statin treatment. Eur J Clin Invest, 2003, 33:976–982.
Mitka M. Amid lingering questions, FDA reprieves LDL cholesterol-lowering
medication. JAMA, 2009, 301:813-815.
Mora S. Advanced lipoprotein testing and subfractionation are
not (yet) ready for routine clinical use. Circulation, 2009,
119:2396–2404.
Mora S, Rifai N, Buring JE, Ridker PM. Comparison of LDL
cholesterol concentrations by Friedewald calculation and
direct measurement in relation to cardiovascular events in 27
331 women. Clin Chem, 2009, 55:888–894.
Movva R, Rader DJ. Laboratory assessment of HDL heterogeneity
and function. Clin Chem, 2008, 54:788–800.
Murabito JM, Pencina MJ, Nam B-H, et al. Sibling cardiovascular
disease as a risk factor for cardiovascular disease in middleaged
adults. JAMA, 2005, 294:3117–3123.
Neuvonen PJ, Niemi M, Backman JT. Drug interactions with
lipid-lowering drugs: Mechanisms and clinical relevance. Clin
Pharmacol Ther, 2006, 80:565–581.
Norris W, Paredes AH, Lewis JH. Drug-induced liver injury in
2007. Curr Opin Gastroenterol, 2008, 24:287–297.
Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al.
ACC/AHA/NHLBI clinical advisory on the use and safety of
statins. Circulation, 2002, 106:1024–1028.
Patrick JE, Kosoglou T, Stauber KL, et al. Disposition of the
selective cholesterol absorption inhibitor ezetimibe in healthy
male subjects. Drug Metab Disp, 2002, 30:430–437.
Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation
and cardiovascular disease. Application to clinical and
public health practice. A statement for healthcare professionals
from the Centers for Disease Control and Prevention and the
American Heart Association. Circulation, 2003, 107:499–511.
Pedersen TR, Tobert JA. Benefits and risks of HMG-CoA reductase
inhibitors in the prevention of coronary heart disease. A
reappraisal. Drug Saf, 1996, 14:11–24.
Pennacchio LA, Olivier M, Hubacek JA, et al. An apolipoprotein
influencing triglycerides in humans and mice revealed by comparative
sequencing. Science, 2001, 294:169–173.
Prueksaritanont T, Subramanian R, Fang X, et al. Glucuronidation
of statins in animals and humans: A novel mechanism of statin
lactonization. Drug Metab Disp, 2002a, 30:505–512.
907
CHAPTER 31
DRUG THERAPY FOR HYPERCHOLESTEROLEMIA AND DYSLIPIDEMIA